Home Cart Sign in  
Chemical Structure| 1232410-49-9 Chemical Structure| 1232410-49-9

Structure of VE-821
CAS No.: 1232410-49-9

Chemical Structure| 1232410-49-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

VE-821 is a potent ATP-competitive inhibitor of ATR with Ki/IC50 values of 13 nM/26 nM.

Synonyms: ATR Inhibitor IV

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of VE-821

CAS No. :1232410-49-9
Formula : C18H16N4O3S
M.W : 368.41
SMILES Code : O=C(C1=NC(C2=CC=C(S(=O)(C)=O)C=C2)=CN=C1N)NC3=CC=CC=C3
Synonyms :
ATR Inhibitor IV
MDL No. :MFCD19443686
InChI Key :DUIHHZKTCSNTGM-UHFFFAOYSA-N
Pubchem ID :51000408

Safety of VE-821

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of VE-821

DNA
PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • ATR

    ATR, Ki:13 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
UWB1 + B1 0.313 µM 6 days VE-821 significantly reduced the IC50 of PARPi (olaparib) in resistant cells, indicating that ATRi can preferentially sensitize PARPi-resistant BRCA1-deficient cells to PARPi. PMC5358727
SYr12 0.313 µM 6 days VE-821 significantly reduced the IC50 of PARPi (olaparib) in resistant cells, indicating that ATRi can preferentially sensitize PARPi-resistant BRCA1-deficient cells to PARPi. PMC5358727
SYr13 0.313 µM 6 days VE-821 significantly reduced the IC50 of PARPi (olaparib) in resistant cells, indicating that ATRi can preferentially sensitize PARPi-resistant BRCA1-deficient cells to PARPi. PMC5358727
MHCC-97H cells 38.74 μM VE821 significantly inhibited the proliferation, migration, and colony formation ability of MHCC-97H cells and enhanced apoptosis PMC8742353
Hep3B cells 18.22 μM VE821 significantly inhibited the proliferation, migration, and colony formation ability of Hep3B cells and enhanced apoptosis PMC8742353
HeLa cells 10 μM 8 h To examine the effect of VE-821 on MSL1 mRNA isoforms, results showed that VE-821 did not block MSL1 upregulation. PMC8580136
U2OS cells 10 μM 8 h To examine the effect of VE-821 on MSL1 mRNA isoforms, results showed that VE-821 did not block MSL1 upregulation. PMC8580136
U2OS cells 10μM 24 h To investigate the effect of VE-821 on micronuclei rupture, results showed that VE-821 reduced the fraction of cGAS+ micronuclei PMC10599252
MDA-MB-231 cells 10μM 24 h To investigate the effect of VE-821 on micronuclei rupture, results showed that VE-821 reduced the fraction of cGAS+ micronuclei PMC10599252
HeLa cells 10μM 24 h To investigate the effect of VE-821 on micronuclei rupture, results showed that VE-821 reduced the fraction of cGAS+ micronuclei PMC10599252
AGS cells 1 μM, 2 μM, 5 μM 72 h VE-821 significantly inhibited the proliferation of AGS cells and synergized with cisplatin to enhance its sensitivity. PMC10400920
MKN-45 cells 1 μM, 2 μM, 5 μM 72 h VE-821 significantly inhibited the proliferation of MKN-45 cells and synergized with cisplatin to enhance its sensitivity. PMC10400920

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
immunodeficient mice hepatocellular carcinoma xenograft model intraperitoneal injection 15 mg/kg twice a week for 20 days VE821 significantly inhibited tumor growth in the hepatocellular carcinoma xenograft model without showing significant toxicity PMC8742353
BALB/c nude mice Gastric cancer xenograft model Oral VE-821, intraperitoneal cisplatin VE-821 3 mg/kg, cisplatin 5 mg/kg Every three days for three weeks Combination of VE-821 and cisplatin significantly inhibited tumor growth and increased the expression of DNA damage marker γ-H2AX. PMC10400920

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.57mL

2.71mL

1.36mL

27.14mL

5.43mL

2.71mL

References

 

Historical Records

Categories